Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity
This was a phase III, randomized, double blind, multicenter, 2-arm study evaluating the efficacy and safety of amcenestrant compared with tamoxifen in participants with hormone receptor-positive early breast cancer who…
- Trial name
- AMEERA-6 (NCT05128773)
- Testing
- Amcenestrant, Tamoxifen
- Where
- 2 sites in Chile, China
- Volunteers
- 3 people
- Sponsor
- Sanofi
Early Breast Cancer
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
This is a multi-center, open-label Phase II randomized pre-surgical pharmacodynamics study.
- Trial name
- MONALEESA-1 (NCT01919229)
- Testing
- LEE011 (ribociclib), letrozole
- Where
- 7 sites in United States, Singapore and 1 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Early Rehabilitation After Immediate Reconstruction With TEI in Breast Cancer Patients
The purpose of the study is to find best post-operative rehabilitation protocol after total mastectomy and immediate reconstruction with tissue expander insertion.
- Trial name
- NCT03541161
- Where
- South Korea
- Volunteers
- 115 people
- Sponsor
- Samsung Medical Center
Breast Cancer
Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer
Accelerated partial breast irradiation (APBI) leads to a equivalent local control rate with lower toxicity as external beam irradiation (EBI) after breast conserving surgery (BCS) in a highly selected subgroup of patients with…
- Trial name
- NCT01175694
- Testing
- Interstitial multicatheter brachytherapy
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital Erlangen
Ovarian Epithelial Cancer, Carcinoma in Situ
Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing
In Phase I the sponsor will systematically test conditions for lavage filtration that increase tumor cell fraction without reducing tumor mutation yield.
- Conditions
- Ovarian Epithelial Cancer, Carcinoma in Situ, Ovarian Cancer
- Trial name
- EHUD (NCT04823871)
- Testing
- Speiser-catheter for uterine and tubal lavage
- Where
- 9 sites in Austria, Czechia and 2 more
- Volunteers
- 406 people
- Sponsor
- Paul Speiser, Prof.MD,
Breast Cancer
Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients
The trial will be preceded by a pilot phase study in 5 patients. This will then be followed by the randomized 1:1 phase II trial testing the utility of regional cryotherapy in preventing or reducing paclitaxel-induced peripheral…
- Trial name
- NCT03429972
- Testing
- Elasto-Gel™, Paclitaxel
- Where
- Singapore
- Volunteers
- 51 people
- Sponsor
- National Cancer Centre, Singapore
Dose Escalation, Safety
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies.
- Conditions
- Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors
- Trial name
- NCT01576666
- Testing
- LDE225, BKM120
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
HER2-positive Breast Cancer
Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
This is a non-interventional observational, multi-center cohort study to evaluate patient-reported outcomes in Chinese HER2+ early breast cancer patients undergoing (neo) adjuvant anti-HER2 based therapy and describe changes over…
- Trial name
- NCT06161922
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Fudan University
Breast Cancer, TNBC - Triple-Negative Breast Cancer
To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer
To investigate the efficacy and safety of terbinumab combined with chemotherapy (epirubicin + cyclophosphamide → nab-paclitaxel + carboplatin) in neoadjuvant therapy of triple-negative breast cancer after HIFU.
- Trial name
- HIFU (NCT05491694)
- Testing
- Toripalimab, Epirubicin, High Intensity Focused Ultrasoun
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Early Breast Cancer, Neoadjuvant Therapy
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
This study will look at the efficacy and safety of QL1706 plus albumin-bound paclitaxel and carboplatin in a neoadjuvant setting, in high-risk, TNBC early breast cancer.
- Conditions
- Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
- Trial name
- QUEEN-Dream (NCT06404736)
- Testing
- Bispecific antibody (bsAb) targeting PD-1 and CLTA-4, Albumin-bound paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Fudan University
Colorectal Neoplasms, Breast Neoplasms
Increasing Breast and Colorectal Cancer Screening in the Community
The goal of the proposed study is to conduct a pilot randomized controlled trial (RCT) of Chi gung, a community-based intervention using peer education and tailored navigation to simultaneously improve colorectal (CRC) and breast…
- Trial name
- NCT07748377
- Testing
- Chi gung: Stay Well, Live Well
- Where
- 7 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Breast Cancer
An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This single arm observational study will assess the duration and safety of treatment with trastuzumab in routine clinical practice in participants with early or metastatic HER2-positive breast cancer.
- Trial name
- HERODOT (NCT01187381)
- Testing
- Trastuzumab
- Where
- Romania
- Volunteers
- 250 people
- Sponsor
- Hoffmann-La Roche
Lymphedema, Breast Cancer
Early Detection of Lymphedema With Bio-Electrical Impedance Analysis in Patients After Breast Cancer Surgery
Bio-electrical impedance analysis and Tissue Dielectric Constant measurements are objective methods in clinical usage to detect lymphedema in early stage.
- Trial name
- BIA (NCT02748746)
- Testing
- Bio Impedance Analysis Measurement, Tissue Dielectric Constant Measurement
- Where
- Turkey (Türkiye)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Abant Izzet Baysal University
HER2-positive Breast Cancer
Pyrotinib in HER2-positive Early Breast Cancer
This is a Multi-cohort, Phase II Clinical Study of Neoadjuvant - Adjuvant Pyrotinib in the Treatment of HER2-positive Early Breast Cancer, To evaluate the efficacy and safety of the pyrotinib-containing study regimen in patients…
- Trial name
- NCT06718335
- Testing
- Pyrotinib
- Volunteers
- 156 people
- Sponsor
- Nie Jianyun
Breast Cancer
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2…
- Trial name
- NCT07054190
- Testing
- Inavolisib, Ribociclib, Letrozole
- Where
- 37 sites in United States, Argentina and 5 more
- Volunteers
- 120 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
This 3 arm study will assess the tolerability, safety and efficacy of 3 neoadjuvant treatment regimens in participants with locally advanced, inflammatory or early stage human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00976989
- Testing
- Pertuzumab, Trastuzumab, FEC
- Where
- 55 sites in Bosnia and Herzegovina, Brazil and 18 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
The Immersive Experience of Virtual Reality During Chemotherapy in Patients With Early Breast and Gynecological Cancers: the Patient's Dream Study
"Patient's dream" study is a two-arm randomized controlled trial that will be conducted at Regina Elena National Cancer Institute, IRCCS (Rome), from April 2019 to January 2020.
- Trial name
- NCT05234996
- Testing
- 3 Virtual Reality headset (VR Headset),
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma
Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
This is a single-center, open-label, randomized phase II clinical trial designed to evaluate the efficacy and safety of neoadjuvant Culmerciclib combined with aromatase inhibitor versus aromatase-inhibitor monotherapy in patients…
- Conditions
- Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma, Early-Stage Breast Cancer
- Trial name
- NCT07796880
- Testing
- Culmerciclib, Aromatase Inhibitor (AI)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy
This clinical trial studies how well ultrasound/photoacoustic/elasticity (US/PA/E) imaging works for early identification of tumor response in patients with stage II-III triple-negative breast cancer receiving immunotherapy and…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Trial name
- NCT07862751
- Testing
- Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Emory University
HER2-positive Breast Cancer
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
Evaluation of the potential incremental efficacy and safety of inavolisib in the neoadjuvant endocrine treatment of early-stage HER2-positive, HR-positive, PIK3CA mutant breast cancer.
- Trial name
- GeparPiPPa (NCT05306041)
- Testing
- Inavolisib, PHESGO, Endocrine therapy
- Where
- 62 sites in Germany, Italy and 4 more
- Volunteers
- 170 people
- Sponsor
- GBG Forschungs GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.